Cempra, Inc. CEMP
No live quote for CEMP yet.
- Market cap
- 24.42M
- Revenue (ttm)
- 17.65M
- EPS (ttm)
- -1.89
- Shares out
- 10.50M
- P/E ratio
- -1.23
- Forward P/E
- -3.27
- Volume
- 511.62K
- Avg volume
- 889.81K
- Open
- 2.25
- Previous close
- 2.30
- Beta
- 0.45
- Analysts
- Hold
- Price target
- 4.75
Key statistics
- Enterprise value
- 435.40M
- PEG ratio
- 0.00
- Price / sales
- 1.38
- Price / book
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -74.90%
- Free cash flow
- -51.05M
- Total cash
- 187.01M
- Total debt
- 12.01M
- Return on equity
- -54.82%
- Short % of float
- 11.32%
- 50-day average
- 2.62
- 200-day average
- 3.53
Analyst view
Consensus: hold
- Target (low)
- 2.00
- Target (mean)
- 4.75
- Target (high)
- 10.50
- Strong buy0
- Buy0
- Hold6
- Sell1
- Strong sell1
Next earnings
Consensus EPS estimate -0.17.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 31, 2017 | Baird | up | Underperform | Neutral |
| Aug 9, 2017 | Roth Capital | down | Buy | Neutral |
| Mar 28, 2017 | Gabelli & Co. | down | — | Sell |
| Feb 26, 2017 | Roth Capital | up | — | Buy |
| Dec 29, 2016 | Morgan Stanley | up | — | Equal-Weight |
| Dec 28, 2016 | Ladenburg Thalmann | down | — | Neutral |
About Cempra, Inc.
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing anti-infectives for the acute care and community settings to meet critical medical needs in the treatment of infectious diseases in North America. Its lead product candidate is solithromycin, which is in Phase III clinical trials developed in oral capsules, intravenous, and suspension formulations for the treatment of community-acquired bacterial pneumonia in adults and children, as well as for ophthalmic infections and other indications. The company is also developing fusidic acid, an antibiotic, which is in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections. In addition, it is developing other uses for solithromycin and fusidic acid, as well as analogs from its macrolide platform for non-infectious disease programs; and macrolides for treating diabetic gastroparesis and gastroesophageal reflux disease. It has a collaborative research and development and license agreement with Optimer Pharmaceuticals, Inc. The company was formerly known as Cempra Holdings, LLC and changed its name to Cempra, Inc. in February 2012. Cempra, Inc. was founded in 2005 and is headquartered in Chapel Hill, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cempra.com
News
Your note
Sign in to keep a note on CEMP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GILL DAVID N | Director | Purchase | Jan 2, 2017 | 5,000 |
| GOLDSTEIN DOV A MD | Director | Sale | Mar 7, 2017 | 50 |
| MOORE DAVID | Officer | Purchase | Feb 29, 2016 | 1,500 |
| NEFF P SHERRILL | Director | Disposition (Non Open Market) | Oct 4, 2016 | 2,488 |
| OLDACH DAVID W. | Officer | Option Exercise | Dec 14, 2015 | 1,100 |